Advances and Challenges in Biological Drug Development and Delivery to be Discussed at Symposium Hosted by the Catalent Applied Drug Delivery Institute and JLABS

SOMERSET, N.J. – September 24, 2019 — The Catalent Applied Drug Delivery Institute today announced that along with Columbia University’s Lab-to-Market Accelerator Network and the Translational Therapeutics Accelerator (TRx), it will co-host a one-day symposium titled “Smart Drug Development & Design” at Columbia University, New York, on Wednesday, Oct. 2, 2019

The symposium will be chaired by Cornell Stamoran, Ph.D., Co-Chair of the Catalent Applied Drug Delivery Institute, and will feature Mike Rea, CEO, IDEA Pharma, Jim Spavins, former Head of Pfizer’s Global PTx Pharmaceutical Sciences group, and a diverse group of industry leaders and researchers.

The first half of the symposium will help delegates understand the scientific concepts and technical know-how underpinning early preclinical studies. The second half of the day will transition the focus on strategies for successful drug products: patient-focused drug design; manufacturing; working with partners; and commercialization. The event will also give attendees the opportunity to apply what they have learned in an interactive audience participation session.

Registration and full details of the agenda can be found at

Notes for Editors

About Catalent Applied Drug Delivery Institute

Catalent’s Applied Drug Delivery Institute was founded in 2012 to serve as a link between industry and academia, advance education and training in drug delivery in academia and the industry, accelerate adoption of applied drug delivery technologies to develop better treatments, and foster industry collaboration on major issues pertaining to drug development, formulation, and delivery. It is pursuing a multi-tiered approach of research, strategic counsel, and educational programs to advance the adoption of drug delivery technologies to improve patient outcomes.

For more details on the Catalent Institute, visit and follow the Catalent Institute on Twitter: @DrugDeliveryIns

About Catalent

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs nearly 13,000 people, including approximately 2,400 scientists, at more than 35 facilities across five continents, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit

More products. Better treatments. Reliably supplied.™